Total Payments
$10,720
2024 Payments
$3,036
Companies
38
Transactions
430
Medicare Patients
2,781
Medicare Billing
$297,082
Payment Breakdown by Category
Food & Beverage$10,066 (93.9%)
Travel$626.81 (5.8%)
Education$27.50 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,066 | 427 | 93.9% |
| Travel and Lodging | $626.81 | 1 | 5.8% |
| Education | $27.50 | 2 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $4,831 | 220 | $0 (2024) |
| Gilead Sciences, Inc. | $675.53 | 34 | $0 (2024) |
| Stryker Corporation | $626.81 | 1 | $0 (2024) |
| GENZYME CORPORATION | $431.27 | 18 | $0 (2024) |
| Boston Scientific Corporation | $388.42 | 5 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $349.03 | 15 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $337.52 | 20 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $256.94 | 11 | $0 (2024) |
| Evoke Pharma, Inc. | $251.09 | 12 | $0 (2023) |
| Janssen Biotech, Inc. | $248.66 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,036 | 122 | ABBVIE INC. ($720.32) |
| 2023 | $1,608 | 99 | ABBVIE INC. ($688.15) |
| 2022 | $2,030 | 74 | ABBVIE INC. ($1,486) |
| 2021 | $1,246 | 48 | AbbVie Inc. ($934.23) |
| 2020 | $637.61 | 16 | AbbVie Inc. ($274.95) |
| 2019 | $736.61 | 21 | AbbVie, Inc. ($256.16) |
| 2018 | $849.41 | 27 | AbbVie, Inc. ($321.55) |
| 2017 | $576.50 | 23 | Endogastric Solutions, Inc ($212.25) |
All Payment Transactions
430 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: Immunology | ||||||
| 11/21/2024 | VIVUS LLC | QSYMIA (Drug) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/28/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $30.37 | General |
| Category: Immunology | ||||||
| 10/23/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $2.44 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/17/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: IMMUNOLOGY | ||||||
| 10/16/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $9.83 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/16/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $9.54 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/09/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/06/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $35.26 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $122.72 | General |
| 10/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: Immunology | ||||||
| 10/03/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: VIROLOGY | ||||||
| 09/26/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $29.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/25/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $21.09 | General |
| Category: IMMUNOLOGY | ||||||
| 09/23/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $7.89 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/19/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $12.90 | General |
| Category: IMMUNOLOGY | ||||||
| 09/16/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: Immunology | ||||||
| 09/16/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $8.69 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.72 | General |
| Category: Immunology | ||||||
| 09/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.84 | General |
| 09/11/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/09/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/09/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $3.79 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/05/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.56 | General |
| Category: Neuroscience | ||||||
| 09/04/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $12.46 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 682 | 712 | $366,735 | $66,743 |
| 2022 | 17 | 634 | 658 | $434,232 | $68,496 |
| 2021 | 13 | 694 | 722 | $432,174 | $78,743 |
| 2020 | 16 | 771 | 825 | $487,450 | $83,101 |
Total Patients
2,781
Total Services
2,917
Medicare Billing
$297,082
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 45 | 45 | $67,500 | $9,002 | 13.3% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 42 | 43 | $33,583 | $7,479 | 22.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 119 | 119 | $28,441 | $7,120 | 25.0% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 35 | 35 | $27,300 | $6,223 | 22.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 88 | 91 | $56,875 | $5,455 | 9.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 60 | 68 | $16,184 | $4,874 | 30.1% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 38 | 38 | $19,760 | $4,061 | 20.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 39 | 40 | $12,320 | $4,028 | 32.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 36 | 36 | $13,140 | $3,694 | 28.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 59 | 64 | $10,240 | $3,136 | 30.6% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 24 | 24 | $26,808 | $3,134 | 11.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 23 | 23 | $30,636 | $2,638 | 8.6% |
| 43246 | Insertion of stomach tube using a flexible endoscope | Facility | 2023 | 12 | 13 | $8,164 | $2,004 | 24.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 29 | 36 | $3,708 | $1,398 | 37.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 22 | $3,586 | $1,364 | 38.0% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 15 | 15 | $8,490 | $1,134 | 13.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 68 | 69 | $104,250 | $12,608 | 12.1% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 42 | 42 | $32,802 | $7,387 | 22.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 39 | 39 | $30,420 | $6,851 | 22.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 110 | 113 | $70,625 | $6,464 | 9.2% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2022 | 60 | 61 | $31,720 | $6,252 | 19.7% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 42 | 43 | $47,679 | $6,033 | 12.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 49 | 49 | $15,092 | $4,916 | 32.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 33 | 33 | $43,956 | $4,518 | 10.3% |
| 43246 | Insertion of stomach tube using a flexible endoscope | Facility | 2022 | 15 | 16 | $10,048 | $2,436 | 24.2% |
About Dr. David Lundy, MD
Dr. David Lundy, MD is a Gastroenterology healthcare provider based in Tyler, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881653426.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Lundy, MD has received a total of $10,720 in payments from pharmaceutical and medical device companies, with $3,036 received in 2024. These payments were reported across 430 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($10,066).
As a Medicare-enrolled provider, Lundy has provided services to 2,781 Medicare beneficiaries, totaling 2,917 services with total Medicare billing of $297,082. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Tyler, TX
- Active Since 03/22/2006
- Last Updated 05/20/2011
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1881653426
Products in Payments
- HUMIRA (Biological) $1,081
- DUPIXENT (Biological) $661.42
- LINZESS (Drug) $660.45
- 1788 (Medical Supply) $626.81
- SKYRIZI (Biological) $595.58
- RINVOQ (Biological) $543.85
- MAVYRET (Drug) $506.98
- CREON (Drug) $494.03
- Humira (Biological) $406.37
- VOQUEZNA (Drug) $349.03
- VIBERZI (Drug) $315.02
- XIFAXAN (Drug) $256.94
- GIMOTI (Drug) $251.09
- Epclusa (Drug) $214.98
- ESOPHYX (Device) $212.25
- Overstitch (Device) $166.30
- STELARA (Biological) $157.60
- ZEPOSIA (Drug) $140.45
- IBSRELA (Drug) $139.52
- Mavyret (Drug) $131.77
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Tyler
George Duvall, M.d, M.D
Gastroenterology — Payments: $106,521
Gastroenterology $106,521
Feng Li, Md, MD
Gastroenterology — Payments: $96,743
Gastroenterology $96,743
Richard Seidel, M.d, M.D
Gastroenterology — Payments: $12,761
Gastroenterology $12,761
Kevin Green, M.d, M.D
Gastroenterology — Payments: $10,817
Gastroenterology $10,817
L Freeman, M.d, M.D
Gastroenterology — Payments: $6,332
Gastroenterology $6,332
Elias Fanous, Md, MD
Gastroenterology — Payments: $5,595
Gastroenterology $5,595